QIAGEN N.V. (NYSE: QGEN) reported net sales of $535 million for its second quarter of fiscal 2026, unchanged from the same period a year earlier on both a reported and constant exchange rate (CER) basis, according to a company statement. The result exceeded the company's prior outlook for an approximately 2% CER decline.

The company's growth pillars collectively delivered approximately 5% CER growth during the quarter. Sample technologies led the gains, with consumables growing at a high single-digit CER rate and instruments at a mid-single-digit CER rate. QIAcuity and QIAGEN Digital Insights also contributed to growth. QuantiFERON sales rose 1% CER, with the company citing a significant decline in U.S. immigration testing demand as a limiting factor. QIAstat-Dx faced a challenging comparison against prior-year respiratory testing sales.

Adjusted operating income margin came in at 29.4% for the quarter. Diluted earnings per share were $0.50, while adjusted diluted EPS reached $0.62 on both a reported and CER basis, surpassing the outlook of at least $0.60 CER.

Operating cash flow for the first half of 2026 was $301 million, which the company described as comparable to the first half of 2025.

"We achieved solid growth across key pillars, particularly Sample technologies, QIAcuity and QDI, while navigating continued pressure on instrument spending in the U.S.," said Chief Executive Officer Thierry Bernard.

Chief Financial Officer Roland Sackers noted that the company increased its 2026 dividend by 40% compared with 2025 and said the company continues to evaluate capital deployment opportunities. He also referenced the absorption of adverse currency headwinds and investments following the Parse acquisition.

QIAGEN reaffirmed its full-year 2026 outlook, calling for net sales growth of approximately 1% to 2% CER and adjusted diluted EPS of at least $2.43 CER.